Xbrane Biopharma Q2 2023: A setback but not case altering - Redeye

Redeye considers Xbrane’s Q2 weak due to slower sales ramp-up than anticipated and postponed profitability. We lower our fair value range but the drastic 43% drop observed yesterday reflects an excessively pessimistic and short-term perspective on the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/940140/xbrane-biopharma-q2-2023-a-setback-but-not-case-altering?utm_source=finwire&utm_medium=RSS